# Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers

> **NCT06098742** · NA · RECRUITING · sponsor: **Valenta Pharm JSC** · enrollment: 50 (estimated)

## Conditions studied

- Heartburn
- Acid-dependent Diseases of the Gastrointestinal Tract
- Symptomatic Treatment of Gastric and Duodenal Ulcers

## Interventions

- **DRUG:** Antareit

## Key facts

- **NCT ID:** NCT06098742
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-25
- **Primary completion:** 2024-10-20
- **Final completion:** 2025-09-20
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06098742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06098742, "Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06098742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*